Serum levels of osteoprotegerin and receptor activator of nuclear factor-κB ligand as markers of periprosthetic osteolysis

被引:38
|
作者
Granchi, Donatella
Pellacani, Andrea
Spina, Mauro
Cenni, Elisabetta
Savarino, Lucia Maria
Baldini, Nicola
Giunti, Armando
机构
[1] Ist Ortoped Rizzoli, Lab Pathophysiol Orthoped Implants, I-40136 Bologna, Italy
[2] Ist Ortoped Rizzoli, Orthoped & Traumatol Div 7, I-40136 Bologna, Italy
来源
关键词
D O I
10.2106/JBJS.E.01038
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Previous studies have suggested that the balance between receptor activator of nuclear factor-kappa B ligand (RANKL) and its decoy-receptor osteoprotegerin (OPG) in local tissue seems to play a crucial role in the loosening of the total hip replacement. The aim of this study was to evaluate whether the circulating levels of OPG and RANKL, as well as their ratio, could be different in patients with aseptic loosening compared with patients with stable implants. Methods: One hundred and twenty-eight subjects were recruited. They included thirty-nine patients with osteoarthritis who had not yet undergone total hip arthroplasty, thirty-three patients who had undergone total hip arthroplasty and had clinically and radiographically stable implants, thirty-six patients with aseptic loosening of total hip arthroplasty components, and twenty healthy volunteers. Serum levels of OPG and RANKL were measured with use of an immunoenzymatic method, and in each individual the OPG-to-RANKL ratio was calculated. Results: In every group, a significant correlation was detected between OPG concentration and age (r = 0.58, p < 0.0001), especially in individuals older than fifty years, while gender and underlying disease were not found to influence serum levels of the tested parameters. In comparison with the levels in healthy donors and patients with a stable total hip replacement, the serum levels of OPG were increased in the patients who had not yet had an arthroplasty, those with aseptic loosening of a total hip replacement, and those with a cemented total hip replacement. Moreover, the OPG serum level provided good diagnostic accuracy in detecting the implant failure. A correlation was found between the sum of the osteolytic areas seen radiographically around the femoral stem and the RANKL level (r = 0.38, p = 0.02) and the OPG-to-RANKL ratio (r = -0.29, p = 0.04). Conclusions: An increase in OPG levels may reflect a protective mechanism of the skeleton to compensate for the osteolytic activity that occurs in severe osteoarthritis and in aseptic loosening. Prospective studies are needed to determine whether serum OPG levels could be used as markers for monitoring the stability of the implant, as well as for predicting aseptic loosening.
引用
收藏
页码:1501 / 1509
页数:9
相关论文
共 50 条
  • [41] Changes in serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, IL-6 and TNF-α in patients with a concomitant head injury and fracture
    Lee, Jung Sub
    Ryu, Chang Hoon
    Moon, Nam Hoon
    Kim, Seong-Jang
    Park, Shin Young
    Suh, Kuen Tak
    ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2009, 129 (05) : 711 - 718
  • [42] Receptor activator of nuclear factor κB ligand and osteoprotegerin in men with thyroid cancer
    Mikosch, P.
    Igerc, I.
    Kudlacek, S.
    Woloszczuk, W.
    Gallowitsch, H. J.
    Kresnik, E.
    Stettner, H.
    Grimm, G.
    Lind, P.
    Pietschmann, P.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 (08) : 566 - 573
  • [43] Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL)
    Terpos, Evangelos
    Christoulas, Dimitrios
    Dimopoulos, Meletios-Athanassios
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (11) : 1265 - 1269
  • [44] The role of serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery
    Balsa, Jose A.
    Lafuente, Christian
    Gomez-Martin, Jesus M.
    Galindo, Julio
    Peromingo, Roberto
    Garcia-Moreno, Francisca
    Rodriguez-Velasco, Gloria
    Martinez-Botas, Javier
    Gomez-Coronado, Diego
    Escobar-Morreale, Hector F.
    Botella-Carretero, Jose I.
    JOURNAL OF BONE AND MINERAL METABOLISM, 2016, 34 (06) : 655 - 661
  • [45] Emerging Roles for Osteoprotegerin and Receptor Activator of Nuclear Factor-κB in the Vascular System
    Cozzolino, Mario
    BLOOD PURIFICATION, 2009, 28 (04) : 346 - 347
  • [46] Platelet-rich fibrin increases the osteoprotegerin/receptor activator of nuclear factor-κB ligand ratio in osteoblasts
    Sumida, Ryuta
    Maeda, Toyonobu
    Kawahara, Ichiro
    Yusa, Junko
    Kato, Yasumasa
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (01) : 358 - 365
  • [47] Receptor activator of nuclear factor-κB ligand and osteoprotegerin -: Potential implications for the pathogenesis and treatment of malignant bone diseases
    Hofbauer, LC
    Neubauer, A
    Heufelder, AE
    CANCER, 2001, 92 (03) : 460 - 470
  • [48] Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand in osteoblasts in vivo and in vitro
    Li, Jingwu
    Wang, Guang-Bin
    Peng, Xue
    Zhang, Jing
    Fu, Qin
    MOLECULAR MEDICINE REPORTS, 2016, 13 (01) : 769 - 777
  • [49] Osteoprotegerin and receptor activator of nuclear factor-κB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls
    Vanderborght, A
    Linsen, L
    Thewissen, M
    Geusens, P
    Raus, J
    Stinissen, P
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (08) : 1483 - 1490
  • [50] Temporal and spatial expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand during mandibular distraction in rats
    Zhu, Wei-Qiao
    Wang, Xing
    Wang, Xiao-Xia
    Wang, Zhi-Ying
    JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2007, 35 (02) : 103 - 111